Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.
Market Cap | 2.669 Billion | Shares Outstanding | 48.359 Million | Avg 30-day Volume | 776.935 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.12 |
Price to Revenue | 36.8438 | Debt to Equity | 0.0 | EBITDA | -136.212 Million |
Price to Book Value | 6.5305 | Operating Margin | -307.14209999999997 | Enterprise Value | 1.255 Billion |
Current Ratio | 2.838 | EPS Growth | 0.936 | Quick Ratio | 2.721 |
1 Yr BETA | 0.9411 | 52-week High/Low | 56.09 / 18.7 | Profit Margin | -274.5882 |
Operating Cash Flow Growth | 230.5114 | Free Cash Flow to Firm (FCFF) TTM | 97.688 Million | Free Cash Flow to Equity (FCFE) TTM | -118.828 Million |
Altman Z-Score | 2.0657 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
HEERY CHRISTOPHER CHIEF MEDICAL OFFICER |
|
7,795 | 2023-08-04 | 12 |
|
0 | 2023-06-14 | 1 | |
|
0 | 2023-06-14 | 3 | |
|
0 | 2023-06-14 | 3 | |
|
0 | 2023-06-14 | 1 | |
|
0 | 2023-06-14 | 1 | |
|
0 | 2023-06-14 | 1 | |
ELGHANDOUR RAMI SEE REMARKS |
|
36,169 | 2023-05-31 | 3 |
GILSON MICHELLE CHIEF FINANCIAL OFFICER |
|
9,485 | 2023-05-23 | 2 |
SR ONE CAPITAL MANAGEMENT, LLC |
|
8,984,637 | 2023-05-11 | 1 |
|
4,746,494 | 2022-12-23 | 2 | |
|
4,745,262 | 2022-12-20 | 1 | |
|
4,746,083 | 2022-12-20 | 1 | |
|
4,745,441 | 2022-12-20 | 1 | |
|
4,745,262 | 2022-12-20 | 1 | |
|
4,745,545 | 2022-12-20 | 1 | |
|
4,745,262 | 2022-12-20 | 1 | |
|
6,745,262 | 2022-06-21 | 2 | |
|
4,016,878 | 2022-02-08 | 0 | |
|
2,095,114 | 2022-02-08 | 0 | |
THIBAULT LANCE E SEE REMARKS |
|
0 | 2022-02-03 | 0 |
SR ONE CAPITAL MANAGEMENT, LLC |
|
0 | 2022-02-03 | 1 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ARCELLX INC ACLX | 2023-12-05 17:15:04 UTC | 4.7177 | 0.6023 | 450000 |
ARCELLX INC ACLX | 2023-12-05 16:45:04 UTC | 4.7177 | 0.6023 | 450000 |
ARCELLX INC ACLX | 2023-12-05 16:15:04 UTC | 4.7177 | 0.6023 | 450000 |
ARCELLX INC ACLX | 2023-12-05 15:45:04 UTC | 4.6861 | 0.6339 | 450000 |
ARCELLX INC ACLX | 2023-12-05 15:15:05 UTC | 4.6861 | 0.6339 | 450000 |
ARCELLX INC ACLX | 2023-12-05 14:45:03 UTC | 4.6828 | 0.6372 | 450000 |
ARCELLX INC ACLX | 2023-12-05 14:15:04 UTC | 4.6828 | 0.6372 | 450000 |
ARCELLX INC ACLX | 2023-12-05 13:45:04 UTC | 4.6828 | 0.6372 | 450000 |
ARCELLX INC ACLX | 2023-12-05 13:15:04 UTC | 4.6828 | 0.6372 | 450000 |
ARCELLX INC ACLX | 2023-12-05 12:45:05 UTC | 4.6828 | 0.6372 | 450000 |
ARCELLX INC ACLX | 2023-12-04 22:15:04 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 21:45:03 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 21:15:03 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 20:45:04 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 20:15:05 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 19:45:03 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 19:15:04 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 18:45:04 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 18:15:05 UTC | 4.6828 | 0.6372 | 400000 |
ARCELLX INC ACLX | 2023-12-04 17:45:03 UTC | 4.6828 | 0.6372 | 400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund | ACLX | -571.0 shares, $-19556.75 | 2023-07-31 | N-PORT |
Meeder Funds- Spectrum Fund | ACLX | -2.0 shares, $-71.76 | 2023-09-30 | N-PORT |
VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND | ACLX | -43106.0 shares, $-1546643.28 | 2023-09-30 | N-PORT |